Waldenstrom MacroglobulinemiaSymptoms, Doctors, Treatments, Advances & More
Learn About Waldenstrom Macroglobulinemia
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Dana-Farber Cancer Institute, Bing Center For Waldenstrom's Macroglobulinemia
Shayna Sarosiek is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Sarosiek is rated as an Elite provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses Waldenstrom Macroglobulinemia, Primary Amyloidosis, Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Sarosiek is board certified in Internal Medicine, Hematology, and Medical Oncology.
Vince Lombardi Cancer Clinic
Syed Abutalib is a Hematologist practicing medicine in Milwaukee, Wisconsin. Dr. Abutalib is rated as a Distinguished provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Langerhans Cell Histiocytosis, Relapsed Refractory Multiple Myeloma (RRMM), Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Abutalib is board certified in American Board Of Internal Medicine, Medical Oncology.
MN - Cancer Transplant
Prashant Kapoor is a Hematologist and an Oncologist practicing medicine in Rochester, Minnesota. Dr. Kapoor is rated as an Elite provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Waldenstrom Macroglobulinemia, Primary Amyloidosis, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Transplant.
Background: Bruton s tyrosine kinase inhibitors (BTKi) are used to treat a form of leukemia. But taking BTKi can also increase a person s risk of developing an abnormal heart rhythm. This can cause sudden death. In this natural history study, researchers want to learn how BTKi affects the heart.
Summary: Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)